Par Pulls Out Of Advancis Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration to develop pulsatile amoxicillin formulation is terminated after two Phase III studies failed.
You may also be interested in...
Advancis Files NDA For Pulsatile Amoxicillin
The company does not rule out the possibility of copromoting the first once-daily formulation of the antibiotic as a way of expanding its sales force if Amoxicillin Pulsys is approved.
Advancis Files NDA For Pulsatile Amoxicillin
The company does not rule out the possibility of copromoting the first once-daily formulation of the antibiotic as a way of expanding its sales force if Amoxicillin Pulsys is approved.
Advancis Will Go It Alone On Amoxicillin Pulsys
Firm will file NDA for pulsatile amoxicillin formulation in late 2006/early 2007 following positive Phase III results.